Oxlund CS, et al. - Researchers sought to assess if intensive blood pressure management is well-tolerated and affects risk uniformly across the body mass index (BMI) spectrum via performing a randomized, controlled Systolic Blood Pressure Intervention Trial (SPRINT) including 9,361 individuals ≥50 years at high cardiovascular risk, without diabetes mellitus, and a systolic blood pressure 130-180 mmHg. Participants randomized to intensive vs standard antihypertensive treatment were evaluated for the primary composite efficacy endpoint of acute coronary syndromes, stroke, heart failure, or cardiovascular death. They observed reduced primary efficacy endpoint and increased primary safety endpoint with intensive blood pressure lowering compared with standard targets, consistently across the BMI spectrum. Outcomes thereby suggested no influence of baseline BMI on overall efficacy and safety of intensive blood pressure lowering among high-risk older adults.